Lexicon Pharmaceuticals Inc. (LXRX): What’s the analyst recommendation for LXRX?

Gabelli & Co announced it was Downgrade coverage of Lexicon Pharmaceuticals Inc. in a research note on December 11, 2019. The analysts assigned a Hold rating to the stock. Citigroup rated the stock as a Neutral in a research noted published on November 08, 2019. Gabelli & Co rated the stock as a Buy in a research note published on September 11, 2019.

COATS LONNEL, the President and CEO of Lexicon Pharmaceuticals Inc., bought 50000.0 shares at the valuation of $3.10 during an exchange that occurred on Sep 18, which implies that COATS LONNEL is holding 227,539 shares at the estimation of $155,000 dependent on the most recent closing price.

In another transaction, on Sep 18, EVP and CCO of Lexicon Pharmaceuticals Inc., Santini Alexander A, bought 4500.0 shares at the price of $3.36. After this activity, Santini Alexander A now keeps 18,661 shares of Lexicon Pharmaceuticals Inc., esteemed at $15,115 with the most recent shutting price.

LXRX Recent Trade

The share price of LXRX ascended by $0.26 during the exchanging session on 07/30/20 to exchange at $2.00. Lexicon Pharmaceuticals Inc. stock has an exchanging volume of 16.75 million shares, which is high, contrasted with its 3-months average volume of 1.41M shares. Its market capitalization has now reached to $225.08M.

LXRX Past Trading Activity

The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, LXRX price has rose by 9.89%. In the course of past three months sees the stock go up around 5.82%, while it has lost -37.50% over the past six months and -51.81% since the start of the year.

LXRX Earning History

Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), the firm recorded a revenue of 8.0 billion, which was higher than the gauge of 10.27M made by certain experts. For that equivalent quarter, Lexicon Pharmaceuticals Inc. posted -$0.63 earnings per share (EPS) which was underneath the consensus estimate of -$0.61 by -$0.02, which represents to a reduction by -3.30%.

LXRX Price Performance

Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Lexicon Pharmaceuticals Inc. has seen its stock exchanging -30.80% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +17.65% above its three-month low. A more extensive look sees LXRX exchanging -62.48% beneath its 52-week high and 77.78% above from its 52-week low price.

LXRX Instability & Beta Factor

The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 7.61%, while it has a month to month instability of 7.74%. Ticker has an ATR (Average True Range) of 0.16 and a beta factor of 1.10.

Leave a Comment